Sign in to view content

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)

Dante Joseph Pieramici, MD

Video
Published 2020

Related

Efficacy and Safety Outcomes Over 12 Weeks With OCS-01 Eye Drops in DME From DIAMOND-Stage 1 Trial:Focus on Subgroup by Prior Treatment Status
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2025
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Outcomes of Intravitreal Antivascular Endothelial Growth Factor (VEGF) Therapy for Diabetic Macular Edema in Routine Clinical Practice
John D Pitcher, MD
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more